Eradicating Measurable Residual Disease in Patients With Acute Myeloid Leukemia (AML) Prior to StEm Cell Transplantation (ERASE): A MyeloMATCH Treatment Trial

ERASE is part of the MyeloMATCH initiative, Young Adult Basket and is a Tier 2 study. The study is comparing the use of Cytarabine to Cytarabine and Venetoclax, Daunorubicin/Cytarabine Liposome and Venetoclax, and Azacitidine and Venetoclax.

Start Date23 Oct 2024

Sponsor / Collaborator

Eastern Cooperative Oncology Group

[+1]

NCT05554406 / RecruitingPhase 2IIT

A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who Are Considered High-Risk (Adverse) Acute Myeloid Leukemia As Determined by MYELOMATCH; A MYELOMATCH Clinical Trial

This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML): 1) daunorubicin and cytarabine liposome alone; 2) cytarabine and daunorubicin with venetoclax; 3) azacitidine and venetoclax; 4) daunorubicin and cytarabine liposome and venetoclax. "High-risk" refers to traits that have been known to make the AML harder to treat. Cytarabine is in a class of medications called antimetabolites. It works by slowing or stopping the growth of cancer cells in the body. Daunorubicin is in a class of medications called anthracyclines. It also works by slowing or stopping the growth of cancer cells in the body. Azacitidine is in a class of medications called demethylation agents. It works by helping the bone marrow to produce normal blood cells and by killing abnormal cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. There is evidence that these newer experimental treatment regimens may work better in getting rid of more AML compared to the standard approach of cytarabine and daunorubicin.

Start Date25 Sep 2024

Sponsor / Collaborator

National Cancer Institute

NCT05554419 / Not yet recruitingPhase 2IIT

Eradicating Measurable Residual Disease in Patients With Acute Myeloid Leukemia (AML) Prior to StEm Cell Transplantation (ERASE): A MyeloMATCH Treatment Trial

This phase II MyeloMATCH treatment trial compares cytarabine versus (vs.) cytarabine and venetoclax vs. liposome-encapsulated daunorubicin-cytarabine and venetoclax vs. azacitidine and venetoclax for treating patients who have residual disease after treatment for acute myeloid leukemia (AML). Cytarabine is in a class of medications called antimetabolites. It works by slowing or stopping the growth of cancer cells in the body. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Liposome-encapsulated daunorubicin-cytarabine is a drug formulation that delivers daunorubicin and cytarabine in small spheres called liposomes, which may make the drugs safer or more effective. Azacitidine is a drug that interacts with DNA and leads to the activation of tumor suppressor genes, which are genes that help control cell growth. This study may help the study doctors find out if the different drug combinations are equally effective to the usual approach of cytarabine alone while requiring a shorter duration of treatment. To decide if they are better, the study doctors will be looking to see if the study drugs lead to a higher percentage of patients achieving a deeper remission compared to cytarabine alone.

Start Date16 Aug 2024

Sponsor / Collaborator

National Cancer Institute

100 Clinical Results associated with Cytarabine/Daunorubicin

100 Translational Medicine associated with Cytarabine/Daunorubicin

100 Patents (Medical) associated with Cytarabine/Daunorubicin

209

Literatures (Medical) associated with Cytarabine/Daunorubicin

01 Jan 2025·HEMATOLOGICAL ONCOLOGY

Comparing Outcomes Between CPX‐351 and Fludarabine‐Based Induction in Secondary Acute Myeloid Leukemia in the Real‐World Setting: The Prognostic Role of Measurable Residual Disease

Article

Author: Chies, Maria ; Tedone, Elisabetta ; Vernarecci, Chiara ; Carminati, Enrico ; Nurra, Clara ; Maio, Elena ; Guolo, Fabio ; Fugazza, Giuseppina ; Cea, Michele ; Puglisi, Francesco ; Ferro, Beatrice ; Parodi, Alessia ; Riva, Carola ; Frello, Michela ; Minetto, Paola ; Zecchetti, Giada ; Rosellini, Sara ; Colombo, Nicoletta ; Nozza, Paolo ; Lemoli, Roberto Massimo

ABSTRACT:

Secondary acute myeloid leukemia (s‐AML) is associated with inferior outcomes with conventional chemotherapy, and fludarabine combinations (FLAG‐Ida) have been tested to improve results. More recently, CPX‐351 resulted superior to conventional 3 + 7 in s‐AML patients. In the UK NCRI AML19 trial, AML patients were randomized to receive either FLAG‐Ida or CPX‐351. Subgroup analysis revealed better overall survival (OS) with CPX‐351 in patients with MDS‐related gene mutations. Unfortunately, minimal residual disease (MRD) was evaluated only in a minority of patients. The aim of this study was to further disclose the mechanisms of higher efficacy of CPX‐351 in s‐AML, with a focus on MRD. We analyzed 183 consecutive s‐AML elderly patients (median age 69, range 60–77) treated with CPX‐351 (n = 82) or receiving FLAG‐Ida (n = 101). Complete remission (CR) rate and MRD negativity probability were higher among patients receiving CPX‐351 (MRD negative CR rate of 40/64, 62.5%, compared to 25/55, 45% in patients who received FLAG‐Ida, p < 0.05). Extra‐hematological toxicity was lower in CPX‐351 arm, and 30 days mortality was 3.6% and 8% in patients receiving CPX‐351 or FLAG‐Ida, respectively. Notably, 21/64 (32.8%) CR patients treated with CPX 351 underwent allogeneic stem cell transplantation (HSCT), compared to 5/55 with FLAG‐Ida (9%, p < 0.05). Overall, CPX‐351 treatment resulted in higher OS (median OS 17.7 vs. 11.2 months with FLAG‐Ida, p < 0.05). The better outcome of CPX‐351 compared to FLAG‐Ida in our cohort may be explained by a greater probability of MRD negativity, alongside with an improved tolerance, enabling more s‐AML patients to undergo HSCT.

24 Dec 2024·Blood Advances

Lower-intensity CPX-351 plus venetoclax induction for adults with newly diagnosed AML unfit for intensive chemotherapy

Article

Author: Chakravarthy, Divya ; Faderl, Stefan ; Lin, Tara L. ; Uy, Geoffrey L. ; Baratam, Praneeth ; Walter, Roland B. ; Menno, Diane ; Cheung, Ronald S. ; Winer, Eric S. ; Pullarkat, Vinod ; Wang, Qi ; Stuart, Robert K.

Abstract:

Preclinical data suggest a rationale for combining CPX-351, a dual-drug liposomal encapsulation of daunorubicin and cytarabine, with venetoclax, a B-cell lymphoma-2 inhibitor. This phase 1b study evaluated lower-intensity CPX-351 combined with venetoclax in adults with acute myeloid leukemia (AML) considered unfit/ineligible for intensive chemotherapy. In a dose-exploration phase using a 3+3 design, patients received stepwise dosing of CPX-351 IV on days 1 and 3 plus venetoclax 400 mg orally on days 2 to 21 per cycle to determine the recommended phase 2 dose (RP2D) for this combination. During the expansion phase, additional patients received CPX-351 plus venetoclax at the identified RP2D. The primary end points were the RP2D and safety of CPX-351 combined with venetoclax. Secondary end points included preliminary efficacy and pharmacokinetics. Overall, 35 patients were enrolled in the study. A RP2D of CPX-351 30 units/m2 (daunorubicin 13.2 mg/m2 and cytarabine 30 mg/m2) plus venetoclax 400 mg was established. The safety profile of the combination was consistent with the known safety profiles of CPX-351 and venetoclax. Complete remission (CR)/CR with incomplete hematologic recovery (CRi) was achieved by 17 of 35 patients (49%), all after cycle 1; of these, 14 were negative for measurable residual disease. CR was achieved by 1 of 8 patients (13%) with a mutation in TP53, and CR/CRi was achieved by 15 of 26 patients (58%) with wild-type TP53. This study highlights that lower-intensity therapy of CPX-351 plus venetoclax as induction therapy provides a well-tolerated treatment option in adults with AML deemed unfit for intensive chemotherapy. This trial was registered at www.ClinicalTrials.gov as #NCT04038437.

01 Dec 2024·JOURNAL OF CHROMATOGRAPHY A

Evaluation of size-based distribution of components in VYXEOS® liposomal formulation using asymmetric flow field-flow fractionation

Article

Author: Mudalige, Thilak ; Shakiba, Sheyda ; Siriwardane, Dumindika A. ; Siriwardane, Dumindika A ; Jiang, Wenlei

VYXEOS® is the first FDA-approved dual-API liposomal formulation containing two different chemotherapeutics, daunorubicin and cytarabine at a 1:5 molar ratio. Analysis of bulk formulation does not provide insight to size-based distribution of APIs and excipients, therefore asymmetrical flow field-flow fractionation (AF4) was utilized for the size-based separation of VYXEOS® liposomes and collected size fractions were further analyzed for the concentrations of APIs, lipid excipients, and copper. Analysis results revealed a significant variation in API distribution across the size fractions, with the larger liposomes encapsulating a higher ratio of cytarabine to daunorubicin compared to the smaller liposomes, while lipid excipient composition was held constant across the size range. We attribute the size-based variation of API ratios to structural change during API loading and sequence of API loading. Cytarabine is first passively loaded into liposomes containing copper gluconate, and then daunorubicin is actively loaded using copper gradient where the daunorubicin is retained in the liposomes as a copper complex. This method can be extended to characterize various single and dual-API liposomal nanocarriers during drug product development and/or post market quality control.

News (Medical) associated with Cytarabine/Daunorubicin

18 Dec 2024

·www.globenewswire.com

Akari Therapeutics Announces Key Leadership Appointments

Samir R. Patel, M.D., appointed as Chief Executive Officer Abizer Gaslightwala appointed to Board of Directors BOSTON and LONDON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) today announced the appointment of Samir R. Patel, M.D., as Chief Executive Officer, effective December 16, 2024. Dr. Patel has served as interim Chief Executive Officer since May 2024. Additionally, the Company announced it has appointed Abizer Gaslightwala to its Board of Directors, effective December 16, 2024. Michael Grissinger, a member of the Board of Directors, provided notice of his resignation on December 16, 2024. “Since beginning my role as interim CEO in May 2024, we have worked diligently to close the merger with Peak Bio, which we accomplished in November, and position Akari for continued growth and value creation. Looking ahead, we are focusing our efforts and resources to streamline operations and execute on our portfolio prioritization – our potentially best-in-class ADC platform. I am pleased to solidify my role with the Akari team and look forward to building momentum and driving shareholder value in the near and long term,” commented Dr. Patel, Chief Executive Officer of Akari. About Samir R. Patel, M.D. Dr. Patel currently serves as founder and principal of PranaBio Investments, LLC, a firm providing consulting, strategic advisory, and investment services for small cap biotechnology companies. He is also a consultant to GE Global Research, GE’s innovation engine that is creating novel products and solutions across several sectors including biomanufacturing and biotechnology. He has more than 20 years of experience in life sciences including founding SPEC Pharma, LLC, a company that develops and manufactures injectables used in human and veterinary applications. Previously, Dr. Patel held multiple roles in Medical Affairs with Centocor, Inc. (now Johnson & Johnson Innovative Medicine, part of Johnson & Johnson). He holds multiple patents, has been an author on several publications and has been an investigator in numerous clinical research studies. He has served on the boards of several public companies, including Rezolute Bio. Dr. Patel received his medical degree from the Medical College of Ohio and completed his internal medicine internship, residency, and rheumatology fellowship at The University of New Mexico School of Medicine Affiliated Hospitals. About Abizer Gaslightwala Mr. Gaslightwala is a well-established biotechnology / pharmaceutical industry leader with a demonstrated track record of success spanning over 25 years in the development and commercialization of novel medicines across a range of companies and therapeutic areas. Mr. Gaslightwala currently serves as the Senior Vice President and Franchise Head for Oncology at Jazz Pharmaceuticals, where he has full responsibility for a portfolio of products spanning both solid and hematological malignancies that have total annual sales of $1B. These brands include ZIIHERA® for HER2+ cancers, ZEPZELCA® for small cell lung cancer, and RYLAZE®, DEFITELIO®, and VYXEOS® for a range of hematological malignancies. “We are pleased to welcome Abizer to our Board of Directors. We believe the depth and breadth of his development and commercialization leadership and expertise amassed over the course of his career will provide valuable insight as we work to propel Akari to its next phase of growth. Additionally, we would like to thank Michael for his years of service on our board. His perspective and guidance have played a key role in getting the Company to where we are today,” added Dr. Patel. Mr. Gaslightwala added, “I'm thrilled to join the Akari board and have been extremely compelled by the Company’s unique ADC platform targeting the spliceosome, that has the potential to set a new standard of care for cancer patients. I look forward to working closely with the management team and other members of the board to advance this platform forward and potentially address areas of significant unmet need for cancer patients.” Prior to his current position at Jazz Pharmaceuticals, Mr. Gaslightwala has led and driven growth in several leadership roles at Amgen, Pfizer, and Johnson & Johnson across multiple brands including Kyprolis®, Vectibix®, Neulasta®, XGEVAf®, Repatha®, and ELIQUIS®. His experience spans business unit leadership, brand marketing, sales leadership, commercial pipeline planning, advanced analytics and insights, and business development. Mr. Gaslightwala also helped lead R&D strategic planning within the autoimmune/inflammation portfolio at Johnson & Johnson, as well as lead commercial planning for Remicade® and several novel pipeline molecules focused on rheumatoid arthritis, inflammatory bowel disease, psoriasis, and atopic dermatitis. Additionally, Mr. Gaslightwala advised several life science companies through his time at the Boston Consulting Group (BCG). Mr. Gaslightwala holds a BS in Chemical Engineering from Cornell University, and an MBA from the Sloan School of Management, and a MS in Chemical Engineering from MIT. About Akari Therapeutics Akari Therapeutics, Plc (Nasdaq: AKTX) is a biotechnology company developing advanced therapies for autoimmune, oncology and inflammatory diseases. Akari has two lead assets, investigational nomacopan and an antibody drug conjugate (ADC) platform. Nomacopan is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. The Company’s ADC platform includes novel toxins and linkers coupled with important cancer antibody targets. For more information about Akari, please visit akaritx.com. Cautionary Note Regarding Forward-Looking Statements This press release includes express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), about the Company that involve risks and uncertainties relating to future events and the future performance of the Company. Actual events or results may differ materially from these forward-looking statements. Words such as “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “future,” “opportunity” “will likely result,” “target,” variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding: the business combination and related matters, including, but not limited to, post-closing operations and the outlook for the Company’s business; the Company’s targets, plans, objectives or goals for future operations, including those related to its product candidates; financial projections; future economic performance,; and the assumptions underlying or relating to such statements. These statements are based on the Company’s current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. A number of important factors, including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: the risk that Akari and Peak Bio may not realize the anticipated benefits of the Merger in the time frame expected, or at all; the ability to retain and hire key personnel; potential adverse reactions or changes to business relationships resulting from the Merger; the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the combined business; uncertainties as to the long-term value of Akari’s American Depositary Shares (and the ordinary shares represented thereby), including the dilution caused by Akari’s issuance of additional American Depositary Shares (and the ordinary shares represented thereby) in connection with the Merger; risks related to global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations; potential delays or failures related to research and/or development of the Company’s programs or product candidates; risks related to any loss of the Company’s patents or other intellectual property rights; any interruptions of the supply chain for raw materials or manufacturing for the Company’s product candidates, the nature, timing, cost and possible success and therapeutic applications of product candidates being developed by the Company and/or its collaborators or licensees; the extent to which the results from the research and development programs conducted by the Company, and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; uncertainty of the utilization, market acceptance, and commercial success of the Company’s product candidates; unexpected breaches or terminations with respect to the Company’s material contracts or arrangements; risks related to competition for the Company’s product candidates; the Company’s ability to successfully develop or commercialize its product candidates; potential exposure to legal proceedings and investigations; risks related to changes in governmental laws and related interpretation thereof, including on reimbursement, intellectual property protection and regulatory controls on testing, approval, manufacturing, development or commercialization of any of the Company’s product candidates; the Company’s ability to maintain listing of its ADSs on the Nasdaq Capital Market. While the foregoing list of factors presented here is considered representative, no list should be considered to be a complete statement of all potential risks and uncertainties. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release. Investor Contact: JTC Team, LLCJenene Thomas908.824.0775AKTX@jtcir.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/110aebf9-2683-41c9-ba9d-bf06f7e42054

Executive Change

03 Dec 2024

·investor.jazzpharma.com

Jazz Pharmaceuticals to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting

Data showcased at SABCS and ASH reflect progress and growth of Jazz's research and development in oncology and demonstrate ongoing efforts to redefine what is possible for cancer treatment DUBLIN , Dec. 3, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present two abstracts at the 2024 San Antonio Breast Cancer Symposium (SABCS) from December 10-13 and 13 abstracts at the 66th Annual American Society of Hematology (ASH) Annual Meeting from December 7-10. A trial-in-progress poster presentation at SABCS outlines the trial design of the ongoing Phase 3 EmpowHER-303 trial (NCT06435429), which is evaluating the efficacy and safety of Ziihera® (zanidatamab-hrii) vs trastuzumab with chemotherapy in patients with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, trastuzumab deruxtecan. New data from a Phase 1b/2 study of zanidatamab plus evorpacept (NCT05027139) in patients with pre-treated HER2-positive and HER2-low metastatic breast cancer will be featured as a poster spotlight. "Following the recent FDA approval of Ziihera for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer, we are pleased to present meaningful data at SABCS on the positive impact zanidatamab can have for patients with HER2-expressing cancers. We continue to advance our clinical program for zanidatamab with the goal to improve outcomes for patients with difficult-to-treat HER2-positive cancers. Our development program includes multiple ongoing Phase 3 trials evaluating 1L BTC, 1L GEA, with top-line PFS results expected in the second quarter of 2025, and metastatic breast cancer after T-DXd treatment, supporting the use of zanidatamab after other HER2-targeted therapies," said Rob Iannone , M.D., M.S.C.E., executive vice president, global head of research and development, and chief medical officer of Jazz Pharmaceuticals . "Additionally, we look forward to highlighting 13 abstracts featuring oncology research at ASH 2024, which underscores our commitment to improving standards of care in blood cancer and other hematologic diseases." The full SABCS abstracts are available here. The Jazz and partner-supported presentations at SABCS 2024 are: Ziihera® (zanidatamab-hrii) Presentations Topic Author Presentation Details EmpowHER 303: A phase 3 study to evaluate the efficacy and safety of zanidatamab vs trastuzumab withchemotherapy in patients (pts) with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, trastuzumab deruxtecan Sara M Tolaney, et al. Presentation Type: Poster Session Abstract Number: SESS-1922 Date: Friday December 13, 2024 Time: 12:00-2:00 PM (PST) Zanidatamab in combination with evorpacept in HER2-positive and HER2-low metastatic breast cancer: Results from a phase 1b/2 study Alberto J Montero, et al. Presentation Type: Poster Spotlight Presentation Abstract Number: SESS-2007 Date: Thursday December 12, 2024 Time: 7:00-8:30 AM (PST) The full ASH abstracts are available here. The Jazz and partner-supported presentations at ASH 2024 are: Vyxeos® (daunorubicin and cytarabine) Presentations Topic Author Presentation Details A Randomized Comparison of CPX-351 and FLAG-Ida in Patients WithHigh-Risk Acute Myeloid Leukemia(AML)/Myelodysplastic Syndrome (MDS) And MDS-Related GeneMutations: A Subgroup Analysis of the UK NCRI AML19 Trial Priyanka Mehta , et al. Presentation Type: Oral Presentation Abstract Number: #55 Date: Saturday December 7, 2024 Time: 9:30 AM (PST) AML-MR Mutations Drive the Benefit of CPX-351 over 7+3 in the Pivotal Phase 3 AML Trial Shai O Shimony, et al. Presentation Type: Oral Presentation Abstract Number: #60 Date: Saturday December 7, 2024 Time: 10:45 AM (PST) Phase Ib/II Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, HighRisk Acute Myeloid Leukemia Emmanuel Almanza , et al. Presentation Type: Poster Presentation Abstract Number: #1511 Date: Saturday December 7, 2024 Time: 5:30-7:30 PM (PST) A Randomised Comparison of CPX-351 versus Standard Daunorubicin and Cytarabine plus FractionatedGemtuzumab Ozogamicin in Older AML Adults Without Known AdverseRisk Cytogenetics: Results of the NCRIAML18 Trial Steven Knapper , et al. Presentation Type: Oral Presentation Abstract Number: #59 Date: Saturday December 7, 2024 Time: 10:30 AM (PST) Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combinationwith Gemtuzumab Ozogamicin in Newly Diagnosed Acute MyeloidLeukemia Onyee Chan , et al. Presentation Type: Poster Presentation Abstract Number: #4270 Date: Monday December 9, 2024 Time: 6:00-8:00 PM (PST) A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy IncludingGemtuzumab Ozogamicin (GO) to CPX-351 with GO – A report from the Children's Oncology Group Jessica A Pollard, et al. Presentation Type: Oral Presentation Abstract Number: #967 Date: Monday December 9, 2024 Time: 4:30 PM (PST) Combination of CPX-351 andGemtuzumab Ozogamicin (GO) inRelapsed Refractory (R/R) AcuteMyeloid Leukemia and PostHypomethylating Agent (HMA) FailureHigh-Risk Myelodysplastic Syndrome (HR-MDS) Jayastu Senapati , et al. Presentation Type: Poster Presentation Abstract Number: #2903 Date: Sunday December 8, 2024 Time: 6:00-8:00 PM (PST) Phase Ib/II Study of CPX-351 plusVenetoclax in Patients with Relapsed/Refractory Acute MyeloidLeukemia (AML) Vanthana Bharathi , et al. Presentation Type: Poster Presentation Abstract Number: #4272 Date: Monday December 9, 2024 Time: 6:00-8:00 PM (PST) Rapid, Reliable, and ComprehensiveIdentification of MDS-DefiningCytogenetic Changes By a FISH-Panel Containing Six Probes in a Real-World Population of Patients with Suspected AML Katayoon Shirneshan, et al. Presentation Type: Poster Presentation Abstract Number: #4308 Date: Monday December 9, 2024 Time: 6:00-8:00 PM (PST) Prospective Evaluation of the Impact ofMeasurable Residual Disease (MRD) by Error Corrected Next-GenerationSequencing (NGS) with CPX-351 inAcute Myeloid Leukemia (AML) David Sallman , et al. Presentation Type: Poster Presentation Abstract Number: #4332 Date: Monday December 9, 2024 Time: 6:00-8:00 PM (PST) A Phase 1 Study of CPX-351 Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated Acute Myeloid Leukemia Onyee Chan , et al. Presentation Type: Poster Presentation Abstract Number: #1520 Date: Saturday December 7, 2024 Time: 5:30-7:30 PM (PST) Defitelio® (defibrotide sodium) Presentations Topic Author Presentation Details Genetic Susceptibility in Sinusoidal Obstruction Syndrome/Veno-OcclusiveDisease Ioulia Mavrikou, et al. Presentation Type: Poster presentation Abstract Number: #4778 Date: Monday December 9, 2024 Time: 6:00-8:00 PM (PST) Defibrotide reduces hypercoagulablestate in patients with Sickle Cell Disease-Related Acute ChestSyndrome Edo Schaefer , et al. Presentation Type: Poster presentation Abstract Number: #2515 Date: Sunday December 8, 2024 Time: 6:00-8:00 PM (PST) About Ziihera® (zanidatamab-hrii) Ziihera (zanidatamab-hrii) is a bispecific HER2-directed antibody that binds to two extracellular sites on HER2. Binding of zanidatamab-hrii with HER2 results in internalization leading to a reduction of the receptor on the tumor cell surface. Zanidatamab-hrii induces complement-dependent cytotoxicity ( CDC ), antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). These mechanisms result in tumor growth inhibition and cell death in vitro and in vivo.1 In the United States , Ziihera is indicated for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test.1 The U.S. Food and Drug Administration (FDA) granted accelerated approval for this indication based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).1 Zanidatamab is not approved anywhere else in the world. Zanidatamab is being developed in multiple clinical trials as a targeted treatment option for patients with solid tumors that express HER2. Zanidatamab is being developed by Jazz and BeiGene, Ltd. (BeiGene) under license agreements from Zymeworks, which first developed the molecule. The FDA granted Breakthrough Therapy designation for zanidatamab development in patients with previously treated HER2 gene-amplified BTC, and two Fast Track designations for zanidatamab: one as a single agent for refractory BTC and one in combination with standard-of-care chemotherapy for 1L gastroesophageal adenocarcinoma (GEA). Additionally, zanidatamab has received Orphan Drug designations from FDA for the treatment of BTC and GEA, as well as Orphan Drug designation from the European Medicines Agency for the treatment of BTC and gastric cancer. Important Safety Information for ZIIHERA® WARNING: EMBRYO-FETAL TOXICITY Exposure to ZIIHERA during pregnancy can cause embryo-fetal harm. Advise patientsof the risk and need for effective contraception. WARNINGS AND PRECAUTIONS Embryo-Fetal ToxicityZIIHERA can cause fetal harm when administered to a pregnant woman. In literature reports, use of a HER2-directed antibody during pregnancy resulted in cases of oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Verify the pregnancy status of females of reproductive potential prior to the initiation of ZIIHERA. Advise pregnant women and females of reproductive potential that exposure to ZIIHERA during pregnancy or within 4 months prior to conception can result in fetal harm. Advise females of reproductive potential to use effective contraception during treatment with ZIIHERA and for 4 months following the last dose of ZIIHERA. Left Ventricular DysfunctionZIIHERA can cause decreases in left ventricular ejection fraction (LVEF). LVEF declined by >10% and decreased to <50% in 4.3% of 233 patients. Left ventricular dysfunction (LVD) leading to permanent discontinuation of ZIIHERA was reported in 0.9% of patients. The median time to first occurrence of LVD was 5.6 months (range: 1.6 to 18.7). LVD resolved in 70% of patients. Assess LVEF prior to initiation of ZIIHERA and at regular intervals during treatment. Withhold dose or permanently discontinue ZIIHERA based on severity of adverse reactions. The safety of ZIIHERA has not been established in patients with a baseline ejection fraction that is below 50%. Infusion-Related ReactionsZIIHERA can cause infusion-related reactions (IRRs). An IRR was reported in 31% of 233 patients treated with ZIIHERA as a single agent in clinical studies, including Grade 3 (0.4%), and Grade 2 (25%). IRRs leading to permanent discontinuation of ZIIHERA were reported in 0.4% of patients. IRRs occurred on the first day of dosing in 28% of patients; 97% of IRRs resolved within one day. Prior to each dose of ZIIHERA, administer premedications to prevent potential IRRs. Monitor patients for signs and symptoms of IRR during ZIIHERA administration and as clinically indicated after completion of infusion. Have medications and emergency equipment to treat IRRs available for immediate use. If an IRR occurs, slow, or stop the infusion, and administer appropriate medical management. Monitor patients until complete resolution of signs and symptoms before resuming. Permanently discontinue ZIIHERA in patients with recurrent severe or life-threatening IRRs. DiarrheaZIIHERA can cause severe diarrhea. Diarrhea was reported in 48% of 233 patients treated in clinical studies, including Grade 3 (6%) and Grade 2 (17%). If diarrhea occurs, administer antidiarrheal treatment as clinically indicated. Perform diagnostic tests as clinically indicated to exclude other causes of diarrhea. Withhold or permanently discontinue ZIIHERA based on severity. ADVERSE REACTIONS Serious adverse reactions occurred in 53% of 80 patients with unresectable or metastatic HER2-positive BTC who received ZIIHERA. Serious adverse reactions in >2% of patients included biliary obstruction (15%), biliary tract infection (8%), sepsis (8%), pneumonia (5%), diarrhea (3.8%), gastric obstruction (3.8%), and fatigue (2.5%). A fatal adverse reaction of hepatic failure occurred in one patient who received ZIIHERA. The most common adverse reactions in 80 patients with unresectable or metastatic HER2-positive BTC who received ZIIHERA (≥20%) were diarrhea (50%), infusion-related reaction (35%), abdominal pain (29%), and fatigue (24%). USE IN SPECIFIC POPULATIONS Pediatric UseSafety and efficacy of ZIIHERA have not been established in pediatric patients. Geriatric UseOf the 80 patients who received ZIIHERA for unresectable or metastatic HER2-positive BTC, there were 39 (49%) patients 65 years of age and older. Thirty-seven (46%) were aged 65-74 years old and 2 (3%) were aged 75 years or older. No overall differences in safety or efficacy were observed between these patients and younger adult patients. About Vyxeos® (daunorubicin and cytarabine) liposome for injectionVyxeos is a liposomal combination of daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, a nucleoside metabolic inhibitor. In the U.S., Vyxeos (daunorubicin and cytarabine) liposome for injection is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.3 More information about Vyxeos in the United States, including Full Prescribing Information and BOXED Warning, is available here. Important Safety Information for VYXEOS® WARNING: VYXEOS has different dosage recommendations from other medications that contain daunorubicin and/or cytarabine. Do not substitute VYXEOS for other daunorubicin and/or cytarabine-containing products. VYXEOS should not be given to patients who have a history of serious allergic reaction to daunorubicin, cytarabine, or any of its ingredients. VYXEOS can cause a severe decrease in blood cells (red and white blood cells and cells that prevent bleeding, called platelets) which can result in serious infection or bleeding and possibly lead to death. Your doctor will monitor your blood counts during treatment with VYXEOS. Patients should tell the doctor about new onset fever or symptoms of infection or if they notice signs of bruising or bleeding. VYXEOS can cause heart-related side effects. Tell your doctor about any history of heart disease, radiation to the chest, or previous chemotherapy. Inform your doctor if you develop symptoms of heart failure such as: shortness of breath or trouble breathing swelling or fluid retention, especially in the feet, ankles, or legs unusual tiredness VYXEOS may cause allergic reactions including anaphylaxis. Seek immediate medical attention if you develop signs and symptoms of anaphylaxis such as: trouble breathing severe itching skin rash or hives swelling of the face, lips, mouth, or tongue VYXEOS contains copper and may cause copper overload in patients with Wilson's disease or other copper-processing disorders. VYXEOS can damage the skin if it leaks out of the vein. Tell your doctor right away if you experience symptoms of burning, stinging, or blisters and skin sores at the injection site. VYXEOS can harm your unborn baby. Inform your doctor if you are pregnant, planning to become pregnant, or nursing. Do not breastfeed while receiving VYXEOS. Females and males of reproductive potential should use effective contraception during treatment and for 6 months following the last dose of VYXEOS. The most common side effects are bleeding events, fever, rash, swelling, nausea, sores in the mouth or throat, diarrhea, constipation, muscle pain, tiredness, stomach pain, difficulty breathing, headache, cough, decreased appetite, irregular heartbeat, pneumonia, blood infection, chills, sleep disorders, and vomiting. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Jazz Pharmaceuticals at 1-800-520-5568. About Defitelio® (defibrotide sodium)In the U.S., Defitelio® (defibrotide sodium) injection 80mg/mL received U.S. Food and Drug Administration (FDA) marketing approval on March 30, 2016, and it is indicated for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT) and is the first and only FDA-approved therapy for patients with this rare, potentially fatal complication.6 Please see full Prescribing Information for Defitelio in the United States . In Europe, defibrotide is marketed under the name Defitelio® ▼ (defibrotide). In October 2013, the European Commission granted marketing authorization to Defitelio under exceptional circumstances for the treatment of severe VOD in patients after HSCT therapy. In Europe, Defitelio is indicated in patients over one month of age. ▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system found under section 4.8 of the SmPC (https://www.ema.europa.eu/en/documents/product-information/defitelio-epar-product-information_en.pdf) The full Summary of Product Characteristics of Defitelio in Europe is available here. Important Safety Information for Defitelio® Defitelio should not be given to patients who are: Currently taking anticoagulants or fibrinolytics Allergic to Defitelio or any of its ingredients Defitelio may increase the risk of bleeding in patients with VOD and should not be given to patients with active bleeding. During treatment with Defitelio, patients should be monitored for signs of bleeding. In the event that bleeding occurs during treatment with Defitelio, treatment should be temporarily or permanently stopped. Patients should tell the doctor right away about any signs or symptoms of hemorrhage such as unusual bleeding, easy bruising, blood in urine or stool, headache, confusion, slurred speech, or altered vision. Defitelio may cause allergic reactions including anaphylaxis. Patients who develop signs and symptoms of anaphylaxis such as trouble breathing, severe itching, skin rash or hives, or swelling of the face, lips, mouth or tongue should seek medical attention immediately. The most common side effects of Defitelio are decreased blood pressure, diarrhea, vomiting, nausea and nose bleeds. Defitelio is not approved for the prevention of VOD. It is not indicated in patients with hypersensitivity to defibrotide or any of its excipients or with concomitant use of thrombolytic therapy. About Jazz Pharmaceuticals Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases—often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information. Jazz Pharmaceuticals plc Caution Concerning Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to, statements related to expectations of top-line PFS results in the second quarter of 2025 and other statements that are not historical facts. These forward-looking statements are based on Jazz Pharmaceuticals' current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with pharmaceutical product development, and other risks and uncertainties affecting Jazz Pharmaceuticals and its development programs, including those described from time to time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals plc's Securities and Exchange Commission filings and reports (Commission File No. 001-33500), including Jazz Pharmaceuticals' Annual Report on Form 10-K for the year ended December 31, 2023 , as supplemented by our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 , and future filings and reports by Jazz Pharmaceuticals . Other risks and uncertainties of which Jazz Pharmaceuticals is not currently aware may also affect Jazz Pharmaceuticals' forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof or as of the dates indicated in the forward-looking statements, even if they are subsequently made available by Jazz Pharmaceuticals on its website or otherwise. Jazz Pharmaceuticals undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made. Contacts: Jazz Media Contact: Kristin Bhavnani Head of Global Corporate Communications Jazz Pharmaceuticals plc CorporateAffairsMediaInfo@jazzpharma.com Ireland +353 1 637 2141 U.S. +1 215 867 4948 Jazz Investor Contact: Jeff Macdonald Executive Director, Investor Relations Jazz Pharmaceuticals plc investorinfo@jazzpharma.com Ireland +353 1 634 3211 U.S. +1 650 496 2717 View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-present-advancements-in-solid-tumors-and-blood-cancer-research-at-san-antonio-breast-cancer-symposium-and-american-society-of-hematology-annual-meeting-302320929.html SOURCE Jazz Pharmaceuticals plc

Phase 3Clinical ResultDrug ApprovalFast TrackBreakthrough Therapy

04 Sep 2024

·www.globenewswire.com

Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors

The appointments of Dr. Karen Smith and Dr. Luke Walker to the Board bring extensive operational and clinical development experience to support corporate and pipeline strategyPHILADELPHIA, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced the appointments of Karen Smith, MD, PhD, MBA, LLM and Luke Walker, MD, to its Board of Directors. “Karen and Luke’s vast experience and proven leadership in the biopharmaceutical industry are tremendous assets for Context at this pivotal stage of our growth," said Martin Lehr, CEO of Context Therapeutics. “Karen’s extensive oncology drug development, regulatory, and strategy experience will be invaluable as Context continues to advance its pipeline. Luke brings an extensive track record in oncology drug development, including recent experience developing T cell engaging bispecific antibodies.” Mr. Lehr continued, “These additions supplement our ongoing effort to build Context into a leading oncology company and advance potential best-in-class T cell engaging bispecifics.” Dr. Karen Smith is a biopharmaceutical thought leader with over 20 years of experience bringing drugs into the clinic and through commercialization. She has been a key contributor to the successful development of multiple approved products in several therapeutic areas, including oncology (Herceptin, Vyxeos), rare disease (Defitelio), cardiology (Irbesartan), dermatology (Voluma, Botox), neuroscience (Abilify) and anti-infectives (Teflaro). Previously, she was Global Head of Research & Development and Chief Medical Officer of Jazz Pharmaceuticals. Earlier in her career, Dr. Smith held senior leadership roles at Allergan, AstraZeneca, and Bristol Myers Squibb. Previously, Dr. Smith served on the Board of Directors of Antares Pharma (acquired by Halozyme for $960 million), Acceleron Pharma (acquired by Merck for $11.5 billion), Mariana Oncology (acquired by Novartis for $1 billion upfront), and Sucampo Pharmaceuticals (acquired by Mallinckrodt for $1.2 billion). Dr. Smith currently serves on the Board of Directors of Aurinia Pharmaceuticals, Capstan Therapeutics, Sangamo Therapeutics, and Skye Bioscience. Dr. Luke Walker has more than 20 years of clinical development experience as both an executive and board member. Most recently, he was the Chief Medical Officer of Harpoon Therapeutics, an oncology-focused biopharmaceutical company where he was responsible for oversight of all aspects of clinical development programs using Harpoon’s TriTAC T-cell engager platform, which was acquired by Merck in 2024 for $680 million. Previously, Dr. Walker was Vice President of Clinical Development at Seagen, where he was the global development lead for Tukysa (tucatinib) through the program’s successful completion of a pivotal registrational trial and successful regulatory approvals. Earlier, Dr. Walker was Senior Vice President of Clinical Development at Cascadian Therapeutics, which was acquired by Seagen in 2018 for $614 million. Dr. Walker began his career as a practicing medical oncologist and hematologist at Providence Regional Medical Center and with the Everett Clinic. Dr. Walker currently serves on the Board of Directors of Zentalis Pharmaceuticals. About Context Therapeutics®Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing medicines for solid tumors. The Company is building an innovative portfolio of clinical-stage T cell engaging bispecific therapeutics, including CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody, and CT-95, a Mesothelin (MSLN) x CD3 bispecific antibody. Context is headquartered in Philadelphia. For more information, please visit www.contexttherapeutics.com or follow the Company on X (formerly Twitter) and LinkedIn. Forward-looking StatementsThis press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, prospects, plans and objectives of management, including words such as “may,” “will,” “expect,” “anticipate,” “look forward,” “plan,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are forward-looking statements. These include, without limitation, statements regarding (i) the ability of the new appointments to support the Company and the advancement of its product candidates; (ii) the ability of the Company to become a leading oncology company; (iii) the potential benefits, characteristics, safety and side effect profile of our product candidates, (iv) the ability of our product candidates to have benefits, characteristics, manufacturability, and a side effect profile that is differentiated and/or better than third party product candidates, (v) the likelihood data will support future development of our product candidates, and (vi) the likelihood of obtaining regulatory approval for our product candidates. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we therefore cannot assure you that our plans, intentions, expectations, or strategies will be attained or achieved. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise. Investor Relations Contact:Jennifer Minai-AzaryContext TherapeuticsIR@contexttherapeutics.com

Executive ChangeAcquisitionCell TherapyImmunotherapy

100 Deals associated with Cytarabine/Daunorubicin

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L01XY01	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Treatment related acute myeloid leukaemia	EU	Jazz Pharmaceuticals Ireland Ltd.	23 Aug 2018
Treatment related acute myeloid leukaemia	IS	Jazz Pharmaceuticals Ireland Ltd.	23 Aug 2018
Treatment related acute myeloid leukaemia	LI	Jazz Pharmaceuticals Ireland Ltd.	23 Aug 2018
Treatment related acute myeloid leukaemia	NO	Jazz Pharmaceuticals Ireland Ltd.	23 Aug 2018
Acute Myeloid Leukemia	US	Celator Pharmaceuticals, Inc.	03 Aug 2017
Acute Myeloid Leukemia with Myelodysplasia-Related Changes	US	Celator Pharmaceuticals, Inc.	03 Aug 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Adult Acute Myeloblastic Leukemia	Phase 3	CN	CSPC ZhongNuo Pharmaceutical (Shijiazhuang) Co. Ltd.	15 Mar 2024
Neoplasm Metastasis	Phase 3	CN	CSPC Zhongnuo Pharmaceutical (Taizhou) Co., Ltd.	01 Jan 2024
Leukemia	Phase 3	CN	CSPC Pharmaceutical Group Ltd.	18 Jul 2022
High Risk Myelodysplastic Syndrome	Phase 3	US	Jazz Pharmaceuticals Plc	13 Dec 2012
High Risk Myelodysplastic Syndrome	Phase 3	CA	Jazz Pharmaceuticals Plc	13 Dec 2012
Acute Myeloid Leukemia with FLT3/ITD Mutation	Phase 2	US	Jazz Pharmaceuticals Plc	05 Jul 2022
Acute Myelomonocytic Leukemia	Phase 2	US	Jazz Pharmaceuticals, Inc.	30 Jan 2022
Acute Myelomonocytic Leukemia	Phase 2	US	MD Anderson Cancer Center Orlando	30 Jan 2022
Residual Neoplasm	Phase 2	US	Jazz Pharmaceuticals Plc	09 Aug 2021
Acute myeloid leukaemia with 11q23 abnormality	Phase 2	US	The University of Texas MD Anderson Cancer Center	30 Dec 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05558124 (ASH2024) Manual	Phase 1	Acute Myeloid Leukemia CD33 Positive	8	CPX-351 + Gemtuzumab Ozogamicin	xpfnnxywzj(radvpgswbr) = observed in 2 patients (1 in Cohort A and 1 in Cohort B) wudaigcehh (qjdplruoke ) View more	Positive	09 Dec 2024
NCT03629171 (ASH2024) Manual	Phase 1/2	Relapsing acute myeloid leukemia \| Refractory acute myeloid leukemia	33	CPX-351	sslagyoxfo(jqmgyyrfuu) = ixuzdbcpxt xqegxepteo (ouleighsby ) View more	Positive	09 Dec 2024
NCT04493164 (ASH2024) Manual	Phase 2	IDH1 Mutation Acute Myeloid Leukemia \| High Risk Myelodysplastic Syndrome IDH1 Mutation	11	CPX-351 + Ivosidenib	ycvquygswo(bjlrqrtifm) = jenjqqaqcc sqhybufoht (thccfdhofd ) View more	Positive	09 Dec 2024
				CPX-351 + Ivosidenib (Adult patients 18 years or older with R/R AML or high-risk MDS harboring an IDH1 mutation)	ycvquygswo(bjlrqrtifm) = qkyyxhgofd sqhybufoht (thccfdhofd ) View more
ASH2024	Not Applicable	Acute Myeloid Leukemia	-	CPX-351	zhapotxgoz(zcqotqopgs) = ucmcgcqdha sfynxxpuds (dlmrnoycor, 0 - 58) View more	-	09 Dec 2024
967A \| AAML1831 (ASH2024)	Phase 3	Acute Myeloid Leukemia FLT3 mutations	721	Arm A (DA+GO)	fsffaqrcxi(edulwfmrgh) = kliskytupv dcyylxykws (tgatousbux, 54.3 - 66.8) View more	Positive	09 Dec 2024
				Arm B (CPX-351+GO)	fsffaqrcxi(edulwfmrgh) = yyebvifknd dcyylxykws (tgatousbux, 44.7 - 57.4) View more
NCT03672539 (2903, ASH2024)	Phase 2	High Risk Myelodysplastic Syndrome \| Refractory acute myeloid leukemia CD33 positive \| diploid karyotype \| complex cytogenetics	47	CPX-351	abwnjlhaxs(ycbhdnkvvg) = otfllaidpa fjusyenyqh (mwfzjlcajk ) View more	Positive	08 Dec 2024
NCRI AML18 (ASH2024)	Phase 2	MDS-related gene mutations	506	CPX-351	brvoirjqbb(kjvvcfyvre) = igkphbdleh bctqxvzxkr (xegtjhatrr, 0.57 - 0.93) View more	Negative	07 Dec 2024
				DAGO2	brvoirjqbb(kjvvcfyvre) = bhnzpswoli bctqxvzxkr (xegtjhatrr, 0.73) View more
ASH2024	Not Applicable	-	-	CPX-351 + Gilteritinib 120mg	nfbsgabcvo(wlzsltgytu) = febrile neutropenia (33.3%), GI related (53.3%), fatigue/weakness (33.3%), and elevated LFTs (13.3%) yojotgrvii (fnumtsbubp )	-	07 Dec 2024
ASH2024	Not Applicable	Acute Myeloid Leukemia with Myelodysplasia-Related Changes	-	CPX-351 (Age <60 years)	oiokdxwljz(tiryfdziaz) = vptiayamyb usioulsywi (yykrncwwet ) View more	-	07 Dec 2024
				CPX-351 (Age ≥60 years)	oiokdxwljz(tiryfdziaz) = zqmkxwwhri usioulsywi (yykrncwwet ) View more
ASH2024	Not Applicable	High Risk Myelodysplastic Syndrome	-	CPX-351	lsxmmaenod(cjqxjiocmz) = lvskgckoyj fgfmziuuft (drnwbxggat ) View more	-	07 Dec 2024
				FLAG-Ida	lsxmmaenod(cjqxjiocmz) = untjhlaknj fgfmziuuft (drnwbxggat ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis